{"id":1900,"date":"2020-06-10T16:20:12","date_gmt":"2020-06-10T16:20:12","guid":{"rendered":"https:\/\/adop.deltasolucoes.com\/?p=1900"},"modified":"2022-01-26T16:26:27","modified_gmt":"2022-01-26T16:26:27","slug":"a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan","status":"publish","type":"post","link":"https:\/\/adop.pt\/en\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/","title":{"rendered":"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d"},"content":{"rendered":"<p class=\"titulonoticia\"><a href=\"https:\/\/adop.deltasolucoes.com\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1901 size-medium alignleft\" src=\"https:\/\/adop.deltasolucoes.com\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280-300x168.jpg\" alt=\"\" width=\"300\" height=\"168\" \/><\/a>A ADoP esteve representada pelo Diretor Executivo, Dr. Ant\u00f3nio J\u00falio Nunes e pela Respons\u00e1vel pelo Sistema de Localiza\u00e7\u00e3o, Dra. Sofia Neves, no Webinar realizado pela WADA, que contou com a presen\u00e7a da canadiana Karine Henrie da WADA e Francesca Rossi da NADO Francesa.<\/p>\n<p>Foram abordados v\u00e1rios temas relacionados com a implementa\u00e7\u00e3o, por parte de uma Organiza\u00e7\u00e3o Antidopagem com autoriza\u00e7\u00e3o para testar, de um programa teste inteligente, eficaz e proporcional ao risco de dopagem entre atletas, sob a sua jurisdi\u00e7\u00e3o, de modo a detetar e impedir tais pr\u00e1ticas e que esteja em conformidade com a norma internacional \u2013 International Standard Testing and Investigation \u2013 ISTI (artigos 4.1 \u2013 4.2)<\/p>\n<p>Assim, de modo a implementar este programa teste, as Organiza\u00e7\u00f5es Antidopagem t\u00eam de ter presentes os seguintes fatores:<\/p>\n<ul>\n<li>O objetivo de a avalia\u00e7\u00e3o de riscos ser claro e abrangente;<\/li>\n<li>A avalia\u00e7\u00e3o de Risco incluir todos os 9 crit\u00e9rios mandat\u00e1rios (a norma internacional anterior contemplava 7 crit\u00e9rios a nova norma vai contemplar mais dois crit\u00e9rios, total de 9):\n<ul>\n<li>Exig\u00eancias f\u00edsicas e requisitos fisiol\u00f3gicos;<\/li>\n<li>Os poss\u00edveis efeitos na melhoria do desempenho que a dopagem pode provocar no desporto\/disciplina desportiva;<\/li>\n<li>As recompensas dispon\u00edveis nos diferentes n\u00edveis do(s) desporto(s) \/ disciplina(s) e \/ ou outros incentivos potenciais que podem levar um praticante desportivo a recorrer \u00e0 dopagem;<\/li>\n<li>Historial em termos de viola\u00e7\u00f5es de normas antidopagem do(s) desporto(s) \/ disciplina(s) desportiva(s);<\/li>\n<li>Pesquisa dispon\u00edvel sobre tend\u00eancias de dopagem (por exemplo, revis\u00e3o por pares, estudos e artigos);<\/li>\n<li>Informa\u00e7\u00e3o recebida \/ intelig\u00eancia desenvolvida sobre poss\u00edveis pr\u00e1ticas de dopagem no desporto;<\/li>\n<li>Os resultados dos ciclos de planeamento de distribui\u00e7\u00e3o de teste anteriores;<\/li>\n<li>Altura da carreira de um atleta onde existe maior probabilidade de beneficiar com subst\u00e2ncias proibidas \u2013 durante a carreira ou durante o ano (numa temporada) em competi\u00e7\u00f5es planeadas e treino.<\/li>\n<\/ul>\n<\/li>\n<li>Existe um v\u00ednculo claro entre a Avalia\u00e7\u00e3o de Risco e o Plano de Distribui\u00e7\u00e3o de Teste;<\/li>\n<li>Grupo alvo de teste claro e proporcional;<\/li>\n<li>A Avalia\u00e7\u00e3o de Risco e o Plano de Distribui\u00e7\u00e3o tem de estar documentado, monitorizado, avaliado e atualizado.<\/li>\n<\/ul>\n<p>A WADA implementou no ADAMS uma ferramenta \u201cADAMS Next Generation\u201d de forma a ajudar as NADOS a monitorizar o seu programa teste e se o mesmo precisa de ser reajustado e atualizado.<\/p>\n<p class=\"titulonoticia\">De forma a ficarem mais claros os temas abordados no Webinar, foi dado o exemplo pr\u00e1tico da NADO Francesa.<\/p>","protected":false},"excerpt":{"rendered":"<p>A ADoP esteve representada pelo Diretor Executivo, Dr. Ant\u00f3nio J\u00falio Nunes e pela Respons\u00e1vel pelo Sistema de Localiza\u00e7\u00e3o, Dra. Sofia Neves, no Webinar realizado pela WADA, que contou com a presen\u00e7a da canadiana Karine Henrie da WADA e Francesca Rossi da NADO Francesa.<\/p>","protected":false},"author":7,"featured_media":1901,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1900","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sem-categoria"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d - ADoP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/adop.pt\/en\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d - ADoP\" \/>\n<meta property=\"og:description\" content=\"A ADoP esteve representada pelo Diretor Executivo, Dr. Ant\u00f3nio J\u00falio Nunes e pela Respons\u00e1vel pelo Sistema de Localiza\u00e7\u00e3o, Dra. Sofia Neves, no Webinar realizado pela WADA, que contou com a presen\u00e7a da canadiana Karine Henrie da WADA e Francesca Rossi da NADO Francesa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/adop.pt\/en\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"ADoP\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61565720170060\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-10T16:20:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-26T16:26:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"499\" \/>\n\t<meta property=\"og:image:height\" content=\"280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"cesar.laranjo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"cesar.laranjo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\"},\"author\":{\"name\":\"cesar.laranjo\",\"@id\":\"https:\/\/adop.pt\/#\/schema\/person\/a6e9cbdf0772431261ac9bffb7978b82\"},\"headline\":\"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d\",\"datePublished\":\"2020-06-10T16:20:12+00:00\",\"dateModified\":\"2022-01-26T16:26:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/adop.pt\/#organization\"},\"image\":{\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg\",\"articleSection\":[\"Sem categoria\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\",\"url\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\",\"name\":\"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d - ADoP\",\"isPartOf\":{\"@id\":\"https:\/\/adop.pt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg\",\"datePublished\":\"2020-06-10T16:20:12+00:00\",\"dateModified\":\"2022-01-26T16:26:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage\",\"url\":\"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg\",\"contentUrl\":\"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg\",\"width\":499,\"height\":280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/adop.pt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/adop.pt\/#website\",\"url\":\"https:\/\/adop.pt\/\",\"name\":\"ADoP\",\"description\":\"Autoridade Antidopagem de Portugal\",\"publisher\":{\"@id\":\"https:\/\/adop.pt\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/adop.pt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/adop.pt\/#organization\",\"name\":\"ADoP\",\"url\":\"https:\/\/adop.pt\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/adop.pt\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/adop.pt\/wp-content\/uploads\/2021\/11\/cropped-adop-logo-bg.jpg\",\"contentUrl\":\"https:\/\/adop.pt\/wp-content\/uploads\/2021\/11\/cropped-adop-logo-bg.jpg\",\"width\":512,\"height\":512,\"caption\":\"ADoP\"},\"image\":{\"@id\":\"https:\/\/adop.pt\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/profile.php?id=61565720170060\",\"https:\/\/www.instagram.com\/antidopagem\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/adop.pt\/#\/schema\/person\/a6e9cbdf0772431261ac9bffb7978b82\",\"name\":\"cesar.laranjo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/adop.pt\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b4f2162739a0f56788d59bb586731d24b41216b1f4bba5ede1255501e7eacaa6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b4f2162739a0f56788d59bb586731d24b41216b1f4bba5ede1255501e7eacaa6?s=96&d=mm&r=g\",\"caption\":\"cesar.laranjo\"},\"url\":\"https:\/\/adop.pt\/en\/author\/cesar-laranjo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d - ADoP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/adop.pt\/en\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/","og_locale":"en_GB","og_type":"article","og_title":"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d - ADoP","og_description":"A ADoP esteve representada pelo Diretor Executivo, Dr. Ant\u00f3nio J\u00falio Nunes e pela Respons\u00e1vel pelo Sistema de Localiza\u00e7\u00e3o, Dra. Sofia Neves, no Webinar realizado pela WADA, que contou com a presen\u00e7a da canadiana Karine Henrie da WADA e Francesca Rossi da NADO Francesa.","og_url":"https:\/\/adop.pt\/en\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/","og_site_name":"ADoP","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61565720170060","article_published_time":"2020-06-10T16:20:12+00:00","article_modified_time":"2022-01-26T16:26:27+00:00","og_image":[{"width":499,"height":280,"url":"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg","type":"image\/jpeg"}],"author":"cesar.laranjo","twitter_card":"summary_large_image","twitter_misc":{"Written by":"cesar.laranjo","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#article","isPartOf":{"@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/"},"author":{"name":"cesar.laranjo","@id":"https:\/\/adop.pt\/#\/schema\/person\/a6e9cbdf0772431261ac9bffb7978b82"},"headline":"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d","datePublished":"2020-06-10T16:20:12+00:00","dateModified":"2022-01-26T16:26:27+00:00","mainEntityOfPage":{"@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/adop.pt\/#organization"},"image":{"@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg","articleSection":["Sem categoria"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/","url":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/","name":"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d - ADoP","isPartOf":{"@id":"https:\/\/adop.pt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage"},"image":{"@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg","datePublished":"2020-06-10T16:20:12+00:00","dateModified":"2022-01-26T16:26:27+00:00","breadcrumb":{"@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#primaryimage","url":"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg","contentUrl":"https:\/\/adop.pt\/wp-content\/uploads\/2022\/01\/webinar_10-06_499x280.jpg","width":499,"height":280},{"@type":"BreadcrumbList","@id":"https:\/\/adop.pt\/a-adop-participou-num-webinar-da-wada-intitulado-risk-assessment-and-test-distribution-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/adop.pt\/"},{"@type":"ListItem","position":2,"name":"A ADoP participou num Webinar da WADA intitulado \u201cRisk Assessment and Test Distribution Plan\u201d"}]},{"@type":"WebSite","@id":"https:\/\/adop.pt\/#website","url":"https:\/\/adop.pt\/","name":"ADoP","description":"Autoridade Antidopagem de Portugal","publisher":{"@id":"https:\/\/adop.pt\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/adop.pt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/adop.pt\/#organization","name":"ADoP","url":"https:\/\/adop.pt\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/adop.pt\/#\/schema\/logo\/image\/","url":"https:\/\/adop.pt\/wp-content\/uploads\/2021\/11\/cropped-adop-logo-bg.jpg","contentUrl":"https:\/\/adop.pt\/wp-content\/uploads\/2021\/11\/cropped-adop-logo-bg.jpg","width":512,"height":512,"caption":"ADoP"},"image":{"@id":"https:\/\/adop.pt\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61565720170060","https:\/\/www.instagram.com\/antidopagem\/"]},{"@type":"Person","@id":"https:\/\/adop.pt\/#\/schema\/person\/a6e9cbdf0772431261ac9bffb7978b82","name":"cesar.laranjo","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/adop.pt\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b4f2162739a0f56788d59bb586731d24b41216b1f4bba5ede1255501e7eacaa6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4f2162739a0f56788d59bb586731d24b41216b1f4bba5ede1255501e7eacaa6?s=96&d=mm&r=g","caption":"cesar.laranjo"},"url":"https:\/\/adop.pt\/en\/author\/cesar-laranjo\/"}]}},"_links":{"self":[{"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/posts\/1900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/comments?post=1900"}],"version-history":[{"count":1,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/posts\/1900\/revisions"}],"predecessor-version":[{"id":1902,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/posts\/1900\/revisions\/1902"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/media\/1901"}],"wp:attachment":[{"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/media?parent=1900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/categories?post=1900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adop.pt\/en\/wp-json\/wp\/v2\/tags?post=1900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}